Results 61 to 70 of about 27,363 (202)

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo, Ditsch, Nina, Friese, Klaus, Kahlert, Steffen, Kümper, Carolin, Lenhard, Miriam, Rückert, Sandra, Untch, Michael   +7 more
core   +2 more sources

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang, Charvi Nanavati, Derek Z. Yang, Liza DeAnnuntis, Mohamed Elmeliegy   +4 more
wiley   +1 more source

Computational and Spectroscopic Insights Into the Rice Bran Derived Glu‐Gln‐Arg‐Pro‐Arg Pentapeptide as an Anticancer Agent: A DFT, Molecular Docking, and Molecular Dynamics Study

International Journal of Quantum Chemistry, Volume 126, Issue 8, April 15, 2026.
Rice bran–derived neutral EQRPR (L‐Glu‐L‐Gln‐L‐Arg‐L‐Pro‐L‐Arg) pentapeptide was structurally and biologically characterized using DFT calculations, vibrational spectroscopy, molecular docking, and molecular dynamics simulations. The DFT/wb97xd/6–31++G(d,p) level of theory showed the best agreement with the experimental spectra.
Gozde Yilmaz, Sefa Celik, Aysen E. Ozel, Sevim Akyuz   +3 more
wiley   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, Volume 20, Issue 4, Page 1061-1073, April 2026.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro

BMC Cancer, 2008
Background Vinca alkaloids are an important class of anticancer agents and semisynthetic vinca alkaloids are developed to improve the therapeutic index of this class of drugs.
Pattyn Greet GO, Lambrechts Hilde AJ, De Pooter Christel MJ, Pauwels Bea, Lardon Filip, Simoens Cindy, Breillout Fabienne, Vermorken Jan B   +7 more
doaj   +1 more source

A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. [PDF]

, 2012
Metastatic non-small cell lung cancer (NSCLC) carries a dismal prognosis. Clinical evidence suggests the existence of an intermediate, or oligometastatic, state when metastases are limited in number and/or location.
Niibe, Yuzuru, Patel, Pretesh R, Salama, Joseph K, Urbanic, James J, Yoo, David S   +4 more
core   +3 more sources

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

Breast
Introduction: Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that has progressed on endocrine therapy. Metronomic administration
Gilles Freyer, Noelia Martinez-Jañez, Bożena Kukielka-Budny, Malgorzata Ulanska, Hugues Bourgeois, Montserrat Muñoz, Serafin Morales, Juan Bayo Calero, Laura Cortesi, Tamás Pintér, Markéta Palácová, Nelli Cherciu, Edgar Petru, Johannes Ettl, Cécilia de Almeida, Gustavo Villanova, Romain Raymond, Christine Ta Thanh Minh, Ana Rodrigues, Marina E. Cazzaniga   +19 more
doaj   +1 more source

Health-related quality of life in advanced non-small cell lung cancer : a methodological appraisal based on a systematic literature review [PDF]

, 2019
Background: The majority of lung cancer patients are diagnosed with advanced non-small cell lung cancer (NSCLC), the bulk of which receive palliative systemic treatment with the goal to provide effective symptom palliation and safeguard health-related ...
Lievens, Yolande, Schrauwen, Wim, Surmont, Veerle, van der Weijst, Lotte   +3 more
core   +2 more sources

Targeted Therapies for Each Subtype of Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review systematically summarizes the advances in targeted therapies for the three major molecular subtypes of breast cancer (BC), highlighting key strategies, agents, and clinical progress to guide personalized treatment. HR‐positive (luminal) BC: Dominated by estrogen receptor (ER) signaling, with endocrine therapies as the cornerstone—including ...
Aiyu Liu, Puchao Peng, Yeke Zhu, Qiuwen Fei, Weiwei Liu, Shizhen Zhang   +5 more
wiley   +1 more source

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]

, 2016
PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly, DuBois, Steven G, Gustafson, W Clay, Hollinger, Fabienne, Karski, Erin E, Long-Boyle, Janel R, Matthay, Katherine K, Nasholm, Nicole M, Shiboski, Stephen, Vo, Kieuhoa T   +9 more
core   +1 more source